179 related articles for article (PubMed ID: 19926311)
1. Prevalent and incident use of androgen deprivation therapy among men with prostate cancer in the United States.
Gilbert SM; Kuo YF; Shahinian VB
Urol Oncol; 2011; 29(6):647-53. PubMed ID: 19926311
[TBL] [Abstract][Full Text] [Related]
2. Reimbursement cuts and changes in urologist use of androgen deprivation therapy for prostate cancer.
Shahinian VB; Kuo YF
BMC Urol; 2015 Apr; 15():25. PubMed ID: 25885745
[TBL] [Abstract][Full Text] [Related]
3. Differential use of medical versus surgical androgen deprivation therapy for patients with metastatic prostate cancer.
Borno HT; Lichtensztajn DY; Gomez SL; Palmer NR; Ryan CJ
Cancer; 2019 Feb; 125(3):453-462. PubMed ID: 30444526
[TBL] [Abstract][Full Text] [Related]
4. Trends and racial differences in the use of androgen deprivation therapy for metastatic prostate cancer.
Carson AP; Howard DL; Carpenter WR; Taylor YJ; Peacock S; Schenck AP; Godley PA
J Pain Symptom Manage; 2010 May; 39(5):872-81. PubMed ID: 20471547
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with the omission of androgen deprivation therapy in radiation-managed high-risk prostate cancer.
Chen YW; Muralidhar V; Mahal BA; Nezolosky MD; Beard CJ; Choueiri TK; Hoffman KE; Martin NE; Orio PF; Sweeney CJ; Feng FY; Trinh QD; Nguyen PL
Brachytherapy; 2016; 15(6):695-700. PubMed ID: 27528590
[TBL] [Abstract][Full Text] [Related]
6. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study.
Gandaglia G; Sun M; Popa I; Schiffmann J; Abdollah F; Trinh QD; Saad F; Graefen M; Briganti A; Montorsi F; Karakiewicz PI
BJU Int; 2014 Dec; 114(6b):E82-E89. PubMed ID: 24612110
[TBL] [Abstract][Full Text] [Related]
7. Locally advanced prostate cancer: a population-based study of treatment patterns.
Lowrance WT; Elkin EB; Yee DS; Feifer A; Ehdaie B; Jacks LM; Atoria CL; Zelefsky MJ; Scher HI; Scardino PT; Eastham JA
BJU Int; 2012 May; 109(9):1309-14. PubMed ID: 22085255
[TBL] [Abstract][Full Text] [Related]
8. Gonadotropin-releasing hormone agonists and acute kidney injury in patients with prostate cancer.
Gandaglia G; Sun M; Hu JC; Novara G; Choueiri TK; Nguyen PL; Schiffmann J; Graefen M; Shariat SF; Abdollah F; Briganti A; Montorsi F; Trinh QD; Karakiewicz PI
Eur Urol; 2014 Dec; 66(6):1125-32. PubMed ID: 24495466
[TBL] [Abstract][Full Text] [Related]
9. Type of Androgen Deprivation Therapy and Risk of Dementia Among Patients With Prostate Cancer in Taiwan.
Huang WK; Liu CH; Pang ST; Liu JR; Chang JW; Liaw CC; Hsu CL; Lin YC; See LC
JAMA Netw Open; 2020 Aug; 3(8):e2015189. PubMed ID: 32865575
[TBL] [Abstract][Full Text] [Related]
10. Guideline-discordant androgen deprivation therapy in localized prostate cancer: patterns of use in the medicare population and cost implications.
Kuykendal AR; Hendrix LH; Salloum RG; Godley PA; Chen RC
Ann Oncol; 2013 May; 24(5):1338-43. PubMed ID: 23277483
[TBL] [Abstract][Full Text] [Related]
11. National Trends in the Utilization of Androgen Deprivation Therapy for Very Low Risk Prostate Cancer.
May A; Henke J; Au D; Raza SJ; Davaro F; Hamilton Z; Siddiqui SA
Urology; 2019 Aug; 130():79-85. PubMed ID: 31047912
[TBL] [Abstract][Full Text] [Related]
12. Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
J Racial Ethn Health Disparities; 2019 Feb; 6(1):133-142. PubMed ID: 29959759
[TBL] [Abstract][Full Text] [Related]
13. Physician visits prior to treatment for clinically localized prostate cancer.
Jang TL; Bekelman JE; Liu Y; Bach PB; Basch EM; Elkin EB; Zelefsky MJ; Scardino PT; Begg CB; Schrag D
Arch Intern Med; 2010 Mar; 170(5):440-50. PubMed ID: 20212180
[TBL] [Abstract][Full Text] [Related]
14. Low rates of bone mineral density measurement in Medicare beneficiaries with prostate cancer initiating androgen deprivation therapy.
Suarez-Almazor ME; Peddi P; Luo R; Nguyen HT; Elting LS
Support Care Cancer; 2014 Feb; 22(2):537-44. PubMed ID: 24146343
[TBL] [Abstract][Full Text] [Related]
15. Androgen deprivation therapy in prostate cancer: are rising concerns leading to falling use?
Krahn M; Bremner KE; Tomlinson G; Luo J; Ritvo P; Naglie G; Alibhai SM
BJU Int; 2011 Nov; 108(10):1588-96. PubMed ID: 21453344
[TBL] [Abstract][Full Text] [Related]
16. Patterns of bone mineral density testing in men receiving androgen deprivation for prostate cancer.
Shahinian VB; Kuo YF
J Gen Intern Med; 2013 Nov; 28(11):1440-6. PubMed ID: 23670565
[TBL] [Abstract][Full Text] [Related]
17. Association of reimbursement policy and urologists' characteristics with the use of medical androgen deprivation therapy for clinically localized prostate cancer.
Quek RG; Master VA; Portier KM; Ward KC; Lin CC; Virgo KS; Lipscomb J
Urol Oncol; 2014 Aug; 32(6):748-60. PubMed ID: 24840868
[TBL] [Abstract][Full Text] [Related]
18. Risks of Major Long-Term Side Effects Associated with Androgen-Deprivation Therapy in Men with Prostate Cancer.
Nguyen C; Lairson DR; Swartz MD; Du XL
Pharmacotherapy; 2018 Oct; 38(10):999-1009. PubMed ID: 30080934
[TBL] [Abstract][Full Text] [Related]
19. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist.
Shahinian VB; Kuo YF; Freeman JL; Goodwin JS
J Natl Cancer Inst; 2006 Jun; 98(12):839-45. PubMed ID: 16788157
[TBL] [Abstract][Full Text] [Related]
20. Real-World Practice Patterns and Predictors of Continuous versus Intermittent Androgen Deprivation Therapy Use for Prostate Cancer in Older Men.
Cheung DC; Alibhai SMH; Martin LJ; Komisarenko M; Dharma C; Warde P; Sridhar SS; Fleshner NE; Kulkarni GS; Finelli A
J Urol; 2021 Oct; 206(4):933-941. PubMed ID: 34032504
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
